Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Amoéba    AMEBA   FR0011051598


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Amoeba : Efficacy of the biocontrol solution against grapevine downy mildew confirmed through the second european field trials

share with twitter share with LinkedIn share with facebook
07/27/2020 | 03:05am EDT


Amoéba: the efficacy of the biocontrol solution against grapevine downy mildew confirmed through the second European field trials campaign.

Chassieu (France), july 27 2020 - AMOEBA (FR0011051598 - AMEBA), - producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces that the results of the second field trials campaign against grapevine downy mildew validate, for the second consecutive year, the efficacy of its biocontrol solution.

Second test campaign in Europe on downy mildew in grapevine

Following the very promising results obtained in 2019 during the first field trials campaign against grapevine downy mildew, Amoéba has just completed its second trials campaign in Europe.

These trials were carried out on behalf of Amoeba by accredited service providers, in several European countries (France: 14 trials / Italy: 3 trials / Germany: 1 trial) and according to protocols recommended by EPPO1 .

These trials were conducted either under natural conditions or, more often, with artificial contamination to trigger the disease and a misting system to maintain the wet conditions favorable to the downy mildew development, even during dry periods.

Trial protocols included up to two reference products (third-party products with a marketing authorization) and an untreated control:

  1. Bordeaux mixture (copper sulphate) was routinely used as the conventional reference product at its maximum authorized dose or, in 5 trials, at a dose varying during the season and close to the practice.
  2. A recently authorized and marketed biocontrol product of natural origin was added in some trials as a biocontrol reference.
  3. An untreated control was used to measure the intensity of disease in the absence of protection and, by comparison, to measure the efficacy of experimental and reference products.

Three experimental products containing the bio-fungicidal active substance of Amoeba (lysate of the amoeba Willaertia magna C2c Maky) were tested: a wettable powder with 60% active substance and 2 liquid suspension concentrates with 20% active substance.

The wettable powder is an improvement of the best-performing formulation in 2019, the suspension concentrates are two new formulations that have been validated under controlled conditions (climatic chamber) during 2019-2020 winter.

The products were applied every 7 to 10 days. Such protocol essentially allows the intrinsic performance of the tested products to be measured and compared, but gives only a partial indication of the possibilities of practical use.

The main objectives were to:

1 EPPO: European and Mediterranean Plant Protection Organization

  1. flesh out the effective dose under agronomic conditions
  2. compare formulations
  3. measure the performance of experimental products combined with a very low dose of copper (tank-mixes).

Climatic conditions: a "downy mildew year" in the South

After a mild winter and a warm spring, the grapevine was particularly advanced in 2020, 1 even 2 weeks ahead of the average of the last 30 years, which is considerable.

In the South and South-West of France as well as in the North of Italy, several episodes of very heavy rainfall (cumulative rainfall of 200 mm or more) during the month of May led to particularly intense downy mildew contaminations while the grapevine - due to the earliness of the vintage - was then in flowering, the most sensitive stage. In Languedoc, Provence, Bordeaux and Gascogne for example, the disease caused serious damage and winegrowers found it difficult to provide acceptable protection during the month of June, despite the wide range of conventional products available.

Thus, 2020 has been a "downy mildew year" in the South, putting fungicide products to the test, a much more difficult situation than in 2019.

On the other hand, the vineyards located further north (Beaujolais, Champagne, Alsace, Loire Valley for example, as well as Germany) experienced a much drier spring, with downy mildew being naturally scarcely present.

Results of the second test campaign

Generally, the efficacy of Amoeba experimental products on leaves is, on average, superior to the

efficacy of the biocontrol reference (authorized product).

Concerning bunch protection, the 2020 results confirm the 2019 observations, with a particularly remarkable protection for a biocontrol product (regularly above 50% efficacy (35-85%) even under exceptional disease pressure).

It should be noted that:

  • in the event of a strong attack at flowering time, the efficacy on mildew on "grey rot" facies may be limited, although it is greater than the efficacy of the biocontrol reference product.
  • even in difficult situations, efficacy on mildew on "brown rot" facies, which develops later on berries, is particularly robust.

These performances on bunches remain lower than that of copper sulphate at its full dose but is, in most trials, significantly higher than the performances of the biocontrol reference: up to over 30%.

It should also be noted that, in two trials, the exceptional climatic situation (in particular the centennial rainfall on 11 May in a trial near Bordeaux) led to massive contamination at the time of grapevine flowering and, in these two trials, Amoéba's experimental products, like the biocontrol reference, showed only limited and transient efficacy (of about 20-30%) under these exceptional conditions.

Positioning the treatment as close as possible to the contaminating rainfall seems to be a key success factor.

As the 2019 trials suggested, the improved formulations of this year determined that the optimal dose rate, even in highly contaminated situations, is between 500 g and 1000 g of active substance per hectare.

In a majority of the comparative trials, the liquid suspension concentrate formulations were slightly superior to the wettable powder formulation at the same dose of active substance.

Mixtures of Amoeba's experimental products with copper at reduced doses performed very well in all cases, providing a high level of protection. However, it is relatively difficult to demonstrate additivity between the active substance and copper, as copper alone often provided good protection even at low dose rates in tests. Such additivity could however be statistically established in a particularly infested Italian trial (98% bunch damage in the control, and 62% efficacy for mixtures with copper, whereas - at equivalent dose - copper alone was 48% and the suspension concentrate at 43% efficacy).

Conclusion: performance on bunches is confirmed and unprecedented for a natural biocontrol product.

This 2020 testing campaign took place under frequently difficult conditions, with an intense disease pressure in May and June, which made it possible to demonstrate the effectiveness of the active substance: the results of 2020 are perfectly consistent with those of 2019. This stability of performance between 2 very different years is a major strength for a plant protection product in general, and for a biocontrol product in particular.

These results make it possible to know the optimal dose, and already approach a positioning of the product in the season: it will be privileged at the very beginning of the cycle, then in period of post flowering.

The good results of combinations with a reduced dose of copper open up prospects for organic farmers in particular, especially if the re-registration of copper at the European level, scheduled for 2026, leads to a reduction of the maximum authorized dose. These results also indicate that this new active substance should make it possible to significantly reduce the use of chemical fungicides in many situations, while ensuring good plant protection.

The partners, who signed a Material Transfer Agreement with Amoéba at the beginning of the year (refer to press release dated April 29,2020), wishing to visit these trials were able to do so. A full report will be presented to them in mid-September.

  • With these first 2 years of field experimentation, Amoéba has totally fulfilled its objectives in the evaluation of its new active substance on downy mildew in grapevine. We now know a precise range of the maximum use dose of the substance, as well as its main characteristics and its high level of performance for a biocontrol product. As the European dossier for the active substance was submitted in May, with a response expected in late 2022/early 2023, we now have two years -2021and 2022- to confirm these results with definitive formulations. In accordance with the schedule already announced, new efficacy trials, required for the application for authorization of formulated products, will be carried out and the results submitted to the Member States once the active substance will be approved" explains Jean-LucSOUCHE, Business Developer plant protection at Amoéba.


Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection estimated globally at €1.6Bn (4). In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (3) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoeba- biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets

(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK



Investors and Media Relations


Grégory BOSSON / Mathieu CALLEUX

General Manager

Agence Calyptus

+33 (0)4 26 69 16 00

+33(0)1 53 65 37 90




This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the Universal Registration Document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 30, 2020 under number D20-0416 (a copy of which is available on www.amoeba-biocide.com).The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.


Amoéba SA published this content on 27 July 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 July 2020 07:05:21 UTC

share with twitter share with LinkedIn share with facebook
All news about AMOÉBA
08/11AMOEBA : publishes a first scientific article concerning its biocontrol applicat..
08/11AMOEBA : publie un premier article scientifique concernant son application bioco..
08/11AMOEBA : Amoéba publishes a first scientific article concerning its biocontrol a..
08/06AMOEBA : announces the issuance of the fifth tranche of 26 bonds convertible int..
08/06AMOEBA : Amoéba annonce l'émission de la 5° tranche d'obligations convertibles e..
07/27AMOEBA : the efficacy of the biocontrol solution against grapevine downy mildew ..
07/27AMOEBA : Efficacy of the biocontrol solution against grapevine downy mildew conf..
07/22AMOEBA : Field tests confirm the efficacy of Amoeba's biocontrol solution on sev..
07/06AMOEBA : Amoéba announces the issuance of the 4th tranche of bonds convertible i..
07/06AMOÉBA : Security operations
More news
Sales 2019 0,12 M 0,14 M 0,14 M
Net income 2019 -7,25 M -8,57 M -8,57 M
Net Debt 2019 3,75 M 4,43 M 4,43 M
P/E ratio 2019 -0,57x
Yield 2019 -
Capitalization 41,7 M 49,3 M 49,2 M
EV / Sales 2018 141x
EV / Sales 2019 67,7x
Nbr of Employees 14
Free-Float 93,8%
Duration : Period :
Amoéba Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMOÉBA
Short TermMid-TermLong Term
Income Statement Evolution
Fabrice Plasson Chief Executive Officer & Director
Pascal Reber Chairman-Supervisory Board
Jacques Goulpeau Chief Operating Officer
Valérie Filiatre Director, Chief Financial & Administrative Officer
Guy Rigaud Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
ADAMA LTD.-7.20%3 127